Skip to content

Observational Prospectif Monocentric Registry of Patients Suffering From VIE

Observational Prospectif Monocentric Registry of Patients Suffering From VIE

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02188056
Acronym
REMOTEV
Enrollment
300
Registered
2014-07-11
Start date
2014-10-01
Completion date
2017-08-31
Last updated
2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolic Disease

Keywords

Venous, Thromboembolic, Pulmonary embolism

Brief summary

Patients with an episode of VTE (DVT and / or PE) have a mortality rate of 16-21% at 1 year after diagnosis. Morbidity associated with VTE is marked by the risk of recurrence, estimated at 30% and estimated at 29% after 8 years of follow post-thrombotic syndrome. For a number of these patients, risk factors have been identified (congenital or acquired thrombophilia, cancer, postpartum, surgery, prolonged immobilization, etc..). In 25-50% of cases, the etiology remains unknown, justifying the need for well-conducted studies to determine other potential risk factors. In addition, the expansion of treatment options with the arrival on the market of new direct oral anticoagulants, allows comparative studies on the effectiveness and frequency of adverse events for each treatment.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* diagnosis of venous thromboembolism established by a validated test (venous Doppler ultrasound of the lower limbs, pulmonary angiography, lung scan ventilation / perfusion), * diagnosis of venous thromboembolism made within 15 days, * the previous inclusion in the register (outpatient or inpatient)

Exclusion criteria

* person doesn't wish to participate in this study

Design outcomes

Primary

MeasureTime frame
incidence of recurrent thromboembolicat 1 year post-diagnosis
bleeding complications incidenceat 1 year post-diagnosis

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026